Wechsler J G, Hutt V, Klör H U, Bode G, Ditschuneit H
Klin Wochenschr. 1982 Jan 15;60(2):97-105. doi: 10.1007/BF01716387.
The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III). Bezafibrate reduced total cholesterol by 16%, whereas HDL-cholesterol increased by 28% and 36% (p less than 0.05). Serumtriglycerides decreased by 59% (450 mg Bezafibrate daily) and by 66% (600 mg Bezafibrate daily) statistically significant (p less than 0.05). In hyperlipidemias type IV, IIb, IIa and V increases of HDL-cholesterol could be observed. The course of LDL-cholesterol was different in the various types of hlp. The postheparin-lipoprotein-lipase (PHLA) was activated by treatment with Bezafibrate from 10.5 +/- 0.7 to 14.7 +/- 0.7 and 15.5 +/- 0.8 mumol FFA/ml/h or by 30% (p less than 0.05). Only few side-effects during treatment with Bezafibrate could be ascertained.
在27例原发性高脂血症（HLP）患者（12例IV型HLP、7例IIb型、3例IIa型、4例V型和1例III型）中研究了苯扎贝特40周长期治疗对脂质和脂蛋白的影响。苯扎贝特使总胆固醇降低了16%，而高密度脂蛋白胆固醇分别升高了28%和36%（p<0.05）。血清甘油三酯分别降低了59%（每日450mg苯扎贝特）和66%（每日600mg苯扎贝特），具有统计学意义（p<0.05）。在IV型、IIb型、IIa型和V型高脂血症中可观察到高密度脂蛋白胆固醇升高。不同类型的HLP中低密度脂蛋白胆固醇的变化过程有所不同。苯扎贝特治疗后，肝素后脂蛋白脂肪酶（PHLA）从10.5±0.7激活至14.7±0.7和15.5±0.8μmol游离脂肪酸/ml/小时，即升高了30%（p<0.05）。使用苯扎贝特治疗期间仅发现少数副作用。
